Attenuated, oncolytic, but not wild-type measles virus infection has pleiotropic effects on human neutrophil function

Journal of Immunology

Volumn 188, Issue 3, 2012, Pages 1002-1010

  Zhang, Yu ^a   Patel, Bella ^a   Dey, Aditi ^a   Ghorani, Ehsan ^a   Rai, Lena ^a   Elham, Mohammed ^a   Castleton, Anna Z ^a   Fielding, Adele K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD150 ANTIGEN; INTERLEUKIN 8; MEASLES VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 1; ONCOLYTIC VIRUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTIGEN EXPRESSION; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; DEGRANULATION; EX VIVO STUDY; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; MEASLES; MICROBIAL ACTIVITY; NEUTROPHIL; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; RNA SYNTHESIS; TARGET CELL; VIRUS ATTENUATION; VIRUS CELL INTERACTION; VIRUS REPLICATION; WILD TYPE;

CYTOKINES; HUMANS; MEASLES; MEASLES VIRUS; NEUTROPHIL ACTIVATION; NEUTROPHILS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VACCINES, ATTENUATED;

EID: 84863017298     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102262     Document Type: Article

References (51)

1. Kirn, D. H. 2000. Replication-selective microbiological agents: fighting cancer with targeted germ warfare. J. Clin. Invest. 105: 837-839. (Pubitemid 30203052)
2. Peng, K. W., G. J. Ahmann, L. Pham, P. R. Greipp, R. Cattaneo, and S. J. Russell. 2001. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98: 2002-2007.
3. Grote, D., S. J. Russell, T. I. Cornu, R. Cattaneo, R. Vile, G. A. Poland, and A. K. Fielding. 2001. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97: 3746-3754.
4. Phuong, L. K., C. Allen, K. W. Peng, C. Giannini, S. Greiner, C. J. TenEyck, P. K. Mishra, S. I. Macura, S. J. Russell, and E. C. Galanis. 2003. Use of a vaccine strain of measles virus genetically engineered to produce carcinoem-bryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 63: 2462-2469. (Pubitemid 36605184)
5. Grote, D., R. Cattaneo, and A. K. Fielding. 2003. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res. 63: 6463-6468. (Pubitemid 37255198)
6. Galanis, E., L. C. Hartmann, W. A. Cliby, H. J. Long, P. P. Peethambaram, B. A. Barrette, J. S. Kaur, P. J. Haluska, Jr., I. Aderca, P. J. Zollman, et al. 2010. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 70: 875-882.
7. Stanford, M. M., C. J. Breitbach, J. C. Bell, and G. McFadden. 2008. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr. Opin. Mol. Ther. 10: 32-37. (Pubitemid 351170592)
8. Kemp, T. J., A. T. Ludwig, J. K. Earel, J. M. Moore, R. L. Vanoosten, B. Moses, K. Leidal, W. M. Nauseef, and T. S. Griffith. 2005. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood 106: 3474-3482. (Pubitemid 41609183)
9. Ludwig, A. T., J. M. Moore, Y. Luo, X. Chen, N. A. Saltsgaver, M. A. O'Donnell, and T. S. Griffith. 2004. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette- Guérininduced antitumor activity. Cancer Res. 64: 3386-3390. (Pubitemid 38657909)
10. Suttmann, H., J. Riemensberger, G. Bentien, D. Schmaltz, M. Stöckle, D. Jocham, A. Böhle, and S. Brandau. 2006. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 66: 8250-8257. (Pubitemid 44299194)
11. Wongthida, P., R. M. Diaz, F. Galivo, T. Kottke, J. Thompson, J. Pulido, K. Pavelko, L. Pease, A. Melcher, and R. Vile. 2010. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res. 70: 4539-4549.
12. Breitbach, C. J., J. M. Paterson, C. G. Lemay, T. J. Falls, A. McGuire, K. A. Parato, D. F. Stojdl, M. Daneshmand, K. Speth, D. Kirn, et al. 2007. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15: 1686-1693. (Pubitemid 47289013)
13. Breitbach, C. J., N. S. De Silva, T. J. Falls, U. Aladl, L. Evgin, J. Paterson, Y. Y. Sun, D. G. Roy, J. L. Rintoul, M. Daneshmand, et al. 2011. Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 19: 886-894.
14. Nauseef, W. M. 2007. Isolation of human neutrophils from venous blood. Methods Mol. Biol. 412: 15-20.
15. Devaux, P., V. von Messling, W. Songsungthong, C. Springfeld, and R. Cattaneo. 2007. Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology 360: 72-83.
16. McBrien, J., J. Murphy, D. Gill, M. Cronin, C. O'Donovan, and M. T. Cafferkey. 2003. Measles outbreak in Dublin, 2000. Pediatr. Infect. Dis. J. 22: 580-584. (Pubitemid 36900200)
17. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res. 29: e45.
18. Jones, D. T., K. Ganeshaguru, A. E. Virchis, N. I. Folarin, M. W. Lowdell, A. B. Mehta, H. G. Prentice, A. V. Hoffbrand, and R. G. Wickremasinghe. 2001. Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. Blood 98: 2800-2807.
19. Niessen, H. W., and A. J. Verhoeven. 1992. Differential up-regulation of specific and azurophilic granule membrane markers in electropermeabilized neutrophils. Cell. Signal. 4: 501-509.
20. Watanabe, A., M. Yoneda, F. Ikeda, Y. Terao-Muto, H. Sato, and C. Kai. 2010. CD147/EMMPRIN acts as a functional entry receptor for measles virus on epithelial cells. J. Virol. 84: 4183-4193.
21. Muhlebach, M. D., M. Mateo, P. L. Sinn, S. Prufer, K. M. Uhlig, V. H. Leonard, C. K. Navaratnarajah, M. Frenzke, X. X. Wong, B. Sawatsky, et al. 2011. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature DOI: 10.1038/nature10639.
22. De Clerck, L. S., C. M. De Gendt, C. H. Bridts, N. Van Osselaer, and W. J. Stevens. 1995. Expression of neutrophil activation markers and neutrophil adhesion to chondrocytes in rheumatoid arthritis patients: relationship with disease activity. Res. Immunol. 146: 81-87.
23. Walcheck, B., A. H. Herrera, C. St Hill, P. E. Mattila, A. R. Whitney, and F. R. Deleo. 2006. ADAM17 activity during human neutrophil activation and apoptosis. Eur. J. Immunol. 36: 968-976.
24. Gómez-Gaviro, M. V., C. Domínguez-Jiménez, J. M. Carretero, P. Sabando, I. González-Alvaro, F. Sánchez-Madrid, and F. Díaz-González. 2000. Downregulation of L-selectin expression in neutrophils by nonsteroidal anti-inflammatory drugs: role of intracellular ATP concentration. Blood 96: 3592-3600.
25. van Eeden, S. F., M. E. Klut, B. A.Walker, and J. C. Hogg. 1999. The use of flow cytometry to measure neutrophil function. J. Immunol. Methods 232: 23-43.
26. Tapper, H., A. Karlsson, M. Mörgelin, H. Flodgaard, and H. Herwald. 2002. Secretion of heparin-binding protein from human neutrophils is determined by its localization in azurophilic granules and secretory vesicles. Blood 99: 1785-1793. (Pubitemid 34533054)
27. Abdelghaffar, H., E. M. Mtairag, and M. T. Labro. 1994. Effects of dirithromycin and erythromycylamine on human neutrophil degranulation. Antimicrob. Agents Chemother. 38: 1548-1554. (Pubitemid 24203567)
28. Brancaleone, V., J. Dalli, S. Bena, R. J. Flower, G. Cirino, and M. Perretti. 2011. Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature. J. Immunol. 186: 4905-4914.
29. Simons, M. P., M. A. O'Donnell, and T. S. Griffith. 2008. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol. Oncol. 26: 341-345. (Pubitemid 351885380)
30. Lichtenstein, A., and J. Kahle. 1985. Anti-tumor effect of inflammatory neutrophils: characteristics of in vivo generation and in vitro tumor cell lysis. Int. J. Cancer 35: 121-127. (Pubitemid 15009649)
31. Simons, M. P., K. G. Leidal, W. M. Nauseef, and T. S. Griffith. 2008. TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules. J. Leukoc. Biol. 83: 621-629. (Pubitemid 351966872)
32. Yui, S., M. Mikami, M. Kitahara, and M. Yamazaki. 1998. The inhibitory effect of lycorine on tumor cell apoptosis induced by polymorphonuclear leukocyte-derived calprotectin. Immunopharmacology 40: 151-162. (Pubitemid 28439169)
33. Fujii, Y., S. Kimura, S. Arai, and F. Sendo. 1987. In vivo antitumor effect of lymphokine-activated rodent polymorphonuclear leukocytes. Cancer Res. 47: 6000-6005. (Pubitemid 18018744)
34. Yang, D., Q. Chen, O. Chertov, and J. J. Oppenheim. 2000. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J. Leukoc. Biol. 68: 9-14.
35. Stojdl, D. F., B. Lichty, S. Knowles, R. Marius, H. Atkins, N. Sonenberg, and J. C. Bell. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6: 821-825. (Pubitemid 30469434)
36. Noser, J. A., A. A. Mael, R. Sakuma, S. Ohmine, P. Marcato, P. W. Lee, and Y. Ikeda. 2007. The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol. Ther. 15: 1531-1536. (Pubitemid 47099310)
37. Elankumaran, S., V. Chavan, D. Qiao, R. Shobana, G. Moorkanat, M. Biswas, and S. K. Samal. 2010. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J. Virol. 84: 3835-3844.
38. Ahtiainen, L., C. Mirantes, T. Jahkola, S. Escutenaire, I. Diaconu, P. Osterlund, A. Kanerva, V. Cerullo, and A. Hemminki. 2010. Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus. PLoS One 5: e13859.
39. van Horssen, R., T. L. Ten Hagen, and A. M. Eggermont. 2006. TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11: 397-408.
40. Watanabe, N., Y. Niitsu, H. Umeno, H. Kuriyama, H. Neda, N. Yamauchi, M. Maeda, and I. Urushizaki. 1988. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res. 48: 2179-2183.
41. Fujiwara, K., A. Matsukawa, S. Ohkawara, K. Takagi, and M. Yoshinaga. 2002. Functional distinction between CXC chemokines, interleukin-8 (IL-8), and growth related oncogene (GRO)α in neutrophil infiltration. Lab. Invest. 82: 15-23. (Pubitemid 34072642)
42. Zachariae, C. O., A. O. Anderson, H. L. Thompson, E. Appella, A. Mantovani, J. J. Oppenheim, and K. Matsushima. 1990. Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J. Exp. Med. 171: 2177-2182. (Pubitemid 20200255)
43. Carr, M. W., S. J. Roth, E. Luther, S. S. Rose, and T. A. Springer. 1994. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. USA 91: 3652-3656. (Pubitemid 24139489)
44. Matsushima, K., C. G. Larsen, G. C. DuBois, and J. J. Oppenheim. 1989. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J. Exp. Med. 169: 1485-1490. (Pubitemid 19104979)
45. Cassatella, M. A., V. Huber, F. Calzetti, D. Margotto, N. Tamassia, G. Peri, A. Mantovani, L. Rivoltini, and C. Tecchio. 2006. Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators. J. Leukoc. Biol. 79: 123-132. (Pubitemid 43054257)
46. Griffith, T. S., S. R. Wiley, M. Z. Kubin, L. M. Sedger, C. R. Maliszewski, and N. A. Fanger. 1999. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189: 1343-1354.
47. Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch, C. A. Smith, et al. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682. (Pubitemid 26091143)
48. Ashkenazi, A., R. C. Pai, S. Fong, S. Leung, D. A. Lawrence, S. A. Marsters, C. Blackie, L. Chang, A. E. McMurtrey, A. Hebert, et al. 1999. Safety and anti-tumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104: 155-162.
49. Walczak, H., R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, et al. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5: 157-163. (Pubitemid 29068521)
50. Borregaard, N., O. E. Sørensen, and K. Theilgaard-Mönch. 2007. Neutrophil granules: a library of innate immunity proteins. Trends Immunol. 28: 340-345. (Pubitemid 47077924)
51. Jaovisidha, P., M. E. Peeples, A. A. Brees, L. R. Carpenter, and J. N. Moy. 1999. Respiratory syncytial virus stimulates neutrophil degranulation and chemokine release. J. Immunol. 163: 2816-2820. (Pubitemid 29399210)